Skip to main content
Premium Trial:

Request an Annual Quote

Proxeon Raises $2.4M from VC Investors

NEW YORK (GenomeWeb News) – Danish proteomics firm Proxeon has raised DKK14 million ($2.4 million) in a round of private financing from venture capital investors.

The firm did not say in its statement who the venture capital investors are for this round, but according to the firm's website investment firms Vecata and Inventure Capital are among its investors.

Proxeon said that the investment is expected to be sufficient to help the firm reach positive cash flow. It also noted that it expects to record full-year 2008 revenue growth of more than 60 percent.

Proxeon CEO Martin Winge noted that the firm has shipped more than 100 of its Easy-nLC systems for nanoscale chromatography since its launch in 2006.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.